Literature DB >> 23898368

Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests.

Rolf Teschke1, Christian Frenzel, Johannes Schulze, Alexander Schwarzenboeck, Axel Eickhoff.   

Abstract

AIM: To analyze the validity of applied test criteria and causality assessment methods in assumed Herbalife hepatotoxicity with positive reexposure tests.
METHODS: We searched the Medline database for suspected cases of Herbalife hepatotoxicity and retrieved 53 cases including eight cases with a positive unintentional reexposure and a high causality level for Herbalife. First, analysis of these eight cases focused on the data quality of the positive reexposure cases, requiring a baseline value of alanine aminotransferase (ALT) < 5 upper limit of normal (N) before reexposure, with N as the upper limit of normal, and a doubling of the ALT value at reexposure as compared to the ALT value at baseline prior to reexposure. Second, reported methods to assess causality in the eight cases were evaluated, and then the liver specific Council for International Organizations of Medical Sciences (CIOMS) scale validated for hepatotoxicity cases was used for quantitative causality reevaluation. This scale consists of various specific elements with scores provided through the respective case data, and the sum of the scores yields a causality grading for each individual case of initially suspected hepatotoxicity.
RESULTS: Details of positive reexposure test conditions and their individual results were scattered in virtually all cases, since reexposures were unintentional and allowed only retrospective rather than prospective assessments. In 1/8 cases, criteria for a positive reexposure were fulfilled, whereas in the remaining cases the reexposure test was classified as negative (n = 1), or the data were considered as uninterpretable due to missing information to comply adequately with the criteria (n = 6). In virtually all assessed cases, liver unspecific causality assessment methods were applied rather than a liver specific method such as the CIOMS scale. Using this scale, causality gradings for Herbalife in these eight cases were probable (n = 1), unlikely (n = 4), and excluded (n = 3). Confounding variables included low data quality, alternative diagnoses, poor exclusion of important other causes, and comedication by drugs and herbs in 6/8 cases. More specifically, problems were evident in some cases regarding temporal association, daily doses, exact start and end dates of product use, actual data of laboratory parameters such as ALT, and exact dechallenge characteristics. Shortcomings included scattered exclusion of hepatitis A-C, cytomegalovirus and Epstein Barr virus infection with only globally presented or lacking parameters. Hepatitis E virus infection was considered in one single patient and found positive, infections by herpes simplex virus and varicella zoster virus were excluded in none.
CONCLUSION: Only one case fulfilled positive reexposure test criteria in initially assumed Herbalife hepatotoxicity, with lower CIOMS based causality gradings for the other cases than hitherto proposed.

Entities:  

Keywords:  Herb induced liver injury; Herbal hepatotoxicity; Herbalife hepatotoxicity; Herbalife induced liver injury; Herbs

Year:  2013        PMID: 23898368      PMCID: PMC3724963          DOI: 10.4254/wjh.v5.i7.353

Source DB:  PubMed          Journal:  World J Hepatol


  61 in total

1.  Misconceptions regarding the association between Herbalife products and liver-related case reports in Spain.

Authors:  Kristy Appelhans; Vasilios Frankos; Andrew Shao
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-03       Impact factor: 2.890

2.  Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data.

Authors:  K Appelhans; R Najeeullah; V Frankos
Journal:  Aliment Pharmacol Ther       Date:  2013-04       Impact factor: 8.171

3.  Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Axel Eickhoff
Journal:  Regul Toxicol Pharmacol       Date:  2012-02-21       Impact factor: 3.271

4.  Revisiting acute liver injury associated with herbalife products.

Authors:  Kristy Appelhans; Casey Smith; Ezra Bejar; Y Steve Henig
Journal:  World J Hepatol       Date:  2011-10-27

5.  Acute hepatitis induced by greater celandine (Chelidonium majus).

Authors:  J Benninger; H T Schneider; D Schuppan; T Kirchner; E G Hahn
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

6.  Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury.

Authors:  Timothy J Davern; Naga Chalasani; Robert J Fontana; Paul H Hayashi; Petr Protiva; David E Kleiner; Ronald E Engle; Hanh Nguyen; Suzanne U Emerson; Robert H Purcell; Hans L Tillmann; Jiezhun Gu; Jose Serrano; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2011-08-16       Impact factor: 22.682

Review 7.  Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate?

Authors:  Rolf Teschke; Albrecht Wolff
Journal:  Regul Toxicol Pharmacol       Date:  2010-09-18       Impact factor: 3.271

8.  Hepatitis after the use of germander, a herbal remedy.

Authors:  L Laliberté; J P Villeneuve
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

9.  Acute hepatitis induced by Greater Celandine (Chelidonium majus).

Authors:  F Stickel; G Pöschl; H K Seitz; R Waldherr; E G Hahn; D Schuppan
Journal:  Scand J Gastroenterol       Date:  2003-05       Impact factor: 2.423

10.  Herbal hepatoxicity from Chinese skullcap: A case report.

Authors:  Leslie Yang; Andrew Aronsohn; John Hart; Donald Jensen
Journal:  World J Hepatol       Date:  2012-07-27
View more
  16 in total

1.  Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal.

Authors:  Anna Licata; Antonio Craxì
Journal:  Intern Emerg Med       Date:  2014-02-26       Impact factor: 3.397

2.  Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity.

Authors:  Kristy Appelhans; Raushanah Najeeullah; Vasilios Frankos
Journal:  Intern Emerg Med       Date:  2014-01-28       Impact factor: 3.397

Review 3.  Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?

Authors:  Gaby Danan; Rolf Teschke
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

Review 4.  Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs.

Authors:  Rolf Teschke; Dominique Larrey; Dieter Melchart; Gaby Danan
Journal:  Medicines (Basel)       Date:  2016-07-19

Review 5.  Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Alexander Schwarzenboeck; Johannes Schulze; Axel Eickhoff
Journal:  World J Hepatol       Date:  2014-01-27

Review 6.  Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods.

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Axel Eickhoff
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

Review 7.  Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps.

Authors:  Rolf Teschke; Axel Eickhoff
Journal:  Front Pharmacol       Date:  2015-04-23       Impact factor: 5.810

Review 8.  Traditional Chinese Medicine Induced Liver Injury.

Authors:  Rolf Teschke
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

Review 9.  Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?

Authors:  Rolf Teschke; Axel Eickhoff; Johannes Schulze
Journal:  J Clin Transl Hepatol       Date:  2013-09-15

Review 10.  Causality assessment for suspected DILI during clinical phases of drug development.

Authors:  Arie Regev; Leonard B Seeff; Michael Merz; Sif Ormarsdottir; Guruprasad P Aithal; Jim Gallivan; Paul B Watkins
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.